Hetlioz

Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA)[2] in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD).[3] In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon[4] and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake... [wikipedia]